Corvus Pharmaceuticals, Inc. (简称Corvus Pharmaceuticals) 即将公布其药物Soquelitinib用于治疗特应性皮炎的安慰剂对照1期临床试验中第四队列的研究结果。该公告备受业界关注,因其可能揭示该候选疗法在特定患者群体中的有效性与安全性数据。
Corvus Pharmaceuticals, Inc. (简称Corvus Pharmaceuticals) 即将公布其药物Soquelitinib用于治疗特应性皮炎的安慰剂对照1期临床试验中第四队列的研究结果。该公告备受业界关注,因其可能揭示该候选疗法在特定患者群体中的有效性与安全性数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.